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Calpains, Ca2+-activated cysteine proteases are essential for early embryonic development 
and function in signal transduction, cell adhesion, and apoptosis. Calpains also contribute to 
cataractogenesis, myocardial infarctions, and neurodegenerative diseases such as Alzheimer's. 
The various methods currently available to demonstrate these roles do not directly identify spatial 
or temporal activation of calpain in cells. Therefore, a tool to detect active calpain in situ will be 
useful. 
Calpastatin is the ubiquitous, endogenous inhibitor that specifically binds the active 
conformation of the conventional calpains. Calpastatin consists of four homologous domains 
each containing three subdomains A, B, and C. The crystal structure of a calpastatin C peptide 
mimic bound to the homodimer of calpain domain VI in the presence of Ca2+ provides a model 
for the structure of calpastatin subdomains A and C bound to calpain domains IV and VI (56). 
This structure predicts the calpain domain IV carboxy-terminus is approximately 31 A from the 
bound calpastatin domain I amino-terminus and the calpastatin domain I subdomain A amino-
terminus is approximately 50 A from the calpastatin domain I subdomain C carboxy-terminus 
when bound to calpain. Both are distances that should allow fluorescence resonance energy 
transfer (FRET) between a pair of fluorophores. These interactions provide a strategy to develop 
a FRET based sensor to detect active calpain. 
A strategy to detect endogenous calpain using the binding of fluorophore modified 
calpastatin subdomain A and C peptides has not yet provided positive results. An alternative 
strategy utilizing the binding of calpastatin domain I to calpain 2 has successfully demonstrated 
FRET. Three calpastatin domain I peptides were labeled at a single distinctly located cysteine 
residue near the amino-terminus with maleimide conjugated tetramethylrhodamine or Alexa Fluor 
(AF) 546. Lumio Green specifically binds a rare tetra-cysteine motif not found in native calpain 
2. Insertion of this motif or eGFP at the carboxy-terminus of calpain 2 domain IV provided two 
mechanisms for specific labeling of calpain to serve as donors to six acceptor fluorophore labeled 
calpastatin domain I peptides during in vitro binding assays. All twelve donor-calpain acceptor-
calpastatin pairs demonstrated a calcium dependent increase in a ratio of acceptor emission to 
donor emission (EmA/EmD) indicating the detection of a FRET signal. The increase in EmA/EmD 
ratio was detected in an E. coli crude cell lysate expressing calpain-eGFP to demonstrate the 
approach should also work in the complex cellular environment. As expected, calpastatin, 
calpain 1 and calpain 2 did compete for binding of calpastatin-AF546 to calpain-eGFP. In 
contrast, two calpain substrates, the cytoplasmic tail of Pi integrin and a-casein, did not exhibit 
competition. These results demonstrate that most substrates should not interfere with the binding 
signal when applied in situ, however endogenous classical calpains and calpastatin likely will 
interfere to some extent. Future studies aim to produce a pair of fluorogenic calpastatin 
subdomain peptides that bind calpain and generate FRET to allow detection of endogenous 
calpain in cells. 
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Chapter 1 INTRODUCTION 
Calpains and Their Significance 
Within the calpain family of calcium activated, neutral cysteine proteases, calpains 1 and 
2 are two classical isoforms of the EF-hand subfamily (26). Physiologically, these calpains are 
implicated in the progression of cell cycle, long-term potentiation, cytoskeletal remodeling and 
apoptosis. A critical role for the classical calpains was demonstrated when disruption of the 
CapnA gene was embryonically lethal to mice (66). This gene encodes the small subunit common 
to the heterodimer of the classical calpain isoforms 1, 2 and 9. It was later discovered that 
disruption of the Capnl gene encoding the calpain 2 large subunit was also embryonically lethal 
in mice. These experiments demonstrated that calpain 2 is an essential calpain isoform for 
successful murine fetal development (14). 
Additionally, calpains are implicated in cell adhesion and motility. Calpains have been 
identified in early integrin clusters that form the initial cellular adhesion contacts of bovine aortic 
endothelial cells (2, 3). Calpain activation has been identified in these early integrin clusters 
upstream of Rac activation leading to formation of filopodia, extension of lamellipodia and 
restructuring of the early integrin clusters into focal complexes (17). Furthermore, calpain 
activity has been associated upstream to RhoA activation leading to the formation of stress fibers 
and focal adhesions, the long term integrin adhesions. Together these and other data support a 
role for calpain in integrin mediated cell adhesion and motility. 
Calpains have also been linked to pathological roles in conditions such as muscular 
dystrophy, cataractogenesis, multiple sclerosis, cardiac ischemia, and neurodegenerative diseases 
(5, 23). Of particular interest is calpain's role in Alzheimer's Disease. Aggregation of the 
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amyloid precursor protein (APP) has been associated with the activation of calpain prior to 
apoptosis (5, 32). Presenilin 1 forms the active site of the multiprotein complex y-secretase that is 
responsible for the proteolytic processing of the APP (29). At least in early onset familial 
Alzheimer's disease, there is evidence to support that mutations in the APP binding site of 
presenilin 1 increases cells' susceptibility to apoptosis possibly through phosphoinositide 
stimulated increases in intracellular calcium (6). This increase in calcium may be the mechanism 
by which calpain is activated in Alzheimer's disease. 
Current Methods for Detecting Active Calpain 
The importance of ascertaining calpains' roles in cellular processes led to attempts to 
identify its subcellular localization when active. Calpains 1 and 2 are also known as u and m 
calpain in reference to their respective in vitro calcium requirements; 3-50 uM for calpain 1 and 
0.4-0.8 mM for calpain 2 (18). The submicromolar calcium levels in the global cellular 
environment are not sufficient for activation (23) suggesting additional factors are required for 
activation in vivo. Localization near calcium channels and the endoplasmic reticulum may 
position calpains near areas with short term increases in calcium sufficient for activation. Two 
regions common in both calpains 1 and 2 have the potential to bind membranes. Many identified 
calpain substrates including talin, vimentin, actin, fodrin, and |3 integrins are in fact membrane 
associated proteins (9). In vitro studies monitoring calpain 1 cleavage of fodrin demonstrated 
lower calcium requirements in the presence of phosphatidylserine and phosphatidylinositol (48). 
Based on this evidence calpains may have the ability to bind membranes for localization as well 
as activation. 
The various combinations of methods utilized thus far do not directly identify active 
calpain's localization. These methods include in vitro assays to identify proteins as calpain 
2 
substrates, in situ colocalization of calpain with these substrates and other proteins, and in situ 
calpain overexpression or inhibition. Proteolysis of calpain substrates in cell lysates is used to 
demonstrate a role for active calpain during cell adhesion, apoptosis and Alzheimer's disease (3, 
22, 30, 32, 35). Calpain substrates are initially identified through cleavage of purified proteins in 
vitro, proteolysis of these calpain substrates in whole cell lysates is then demonstrated on western 
blots (30). Cleavage of fluorogenic peptides is also used to identify calpain activity in cells. This 
may demonstrate calpain was active but not where within the cell. Also, it is not certain that 
cleavage of calpain substrates or peptides in cells is directly diagnostic for calpain activity. The 
mechanism of calpain's specific recognition of substrates has yet to be elucidated. Calpains' 
prefer solvent exposed unstructured linker regions on large proteins rather than small peptides for 
substrate cleavage sites (9, 55, 58). Furthermore, calpain substrates such as a-spectrin and tau 
can be cleaved by other proteases including caspase-3 leaving a similar sized cleavage product 
(60). Thus cleavage of calpain substrates may not be exclusive to calpain proteases in vivo. In 
situ overexpression or inhibition of calpain is used to reinforce active calpain's effect on cells 
during potential physiologic and pathologic roles (3, 30). Colocalization of calpains with cleaved 
substrate (e.g. cleaved spectrin) and proteins that serve as markers (ER marker calnexin, Golgi 
marker Rab6, cell membrane phospholipid PIP2 and adhesion transmembrane protein p3 integrin) 
in cells is used to demonstrate active calpain's localization (2, 3, 22). Calpains are visualized 
using either a polyclonal antibody raised against a peptide mimic for the calpain 1 amino-terminal 
residues post proteolytic cleavage or a monoclonal antibody for calpain (47, 48). The polyclonal 
antibody was shown to be selective for native autolyzed calpain 1 but not calpain 2. It does not 
appear that available antibodies that detect autolyzed calpain 2 have been used in cells. As 
discussed above, spectrin is also cleaved by caspase-3 and is not exclusively diagnostic for 
calpain activity. The insufficient selectivity of the antibodies used diminishes direct 
identification of active calpain's localization in cells. Overexpression of calpain in cells does 
give an indication of calpain's potential effects yet the unphysiological levels of the protease may 
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yield exaggerated or harmful effects on cells. In situ inhibition of calpain generally uses small, 
cell permeable inhibitors such as carbobenzoxy-valinyl-phenylalaninal MDL 28170 (MDL), 
Calpain Inhibitor I N-Acetyl-Leu-Leu-Nle (ALLN), or calpeptin (2, 31, 61). These inhibitors 
also inhibit a tyrosine phosphatase (calpeptin), cathepsins B and L (ALLN, MDL), the 
proteasome and other neutral cysteine proteases (ALLN) complicating the correlation of these 
results to calpain's role in cells (21, 37, 39, 50). These methods do not directly identify spatial or 
temporal activation of calpains in cells, a tool to accomplish this would be a useful aid in 
determining calpain's role in cell signaling and disease. 
Calpastatin, the Endogenous Inhibitor of Calpains 
Calpains natural endogenous inhibitor, calpastatin, most specifically inhibits the classical 
calpains. Calpastatin reversibly binds the classical calpains in the presence of calcium, thus it 
specifically binds and inhibits calpains active conformation (41). It is estimated to be less than 
-80 kDa intrinsically unstructured protein (IUP) that migrates anomalously at ~110 kDa by SDS-
PAGE (24). Calpastatin is made up of five domains (figure. 1.1). The function of the first 
domain, the L domain, or leader sequence is relatively unknown but has been suggested to 
regulate L-type Ca2+ channels (40, 42). The remaining four domains (I-IV) show 20-30% 
homology to each other and are each capable of inhibiting calpain with affinities in the order of 
I>IV>III>II (18, 27, 64). Calpastatin domains I-IV each contain three subdomains known as A, 
B, and C. Subdomain B is the sole requirement for inhibition. Subdomains A and C while not 
inhibitory, tightly bind the classical calpains. The tight binding of subdomains A and C and the 
calcium dependent inhibition by subdomain B work together to form the most specific inhibitor 
for the active classical calpains (55). 
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Figure 1.1 Diagram of Full Length Calpastatin 
Full length human calpastatin including the amino-terminal leader sequence and the four 
inhibitory domains (I-IV) is 708 amino acid residues. The four ~140 residue imperfect repeats 
contain three more highly conserved regions designated subdomains A, B, and C (24). The -20 
residue subdomains A and C flank the inhibitory -26 residue subdomain B (55). 
Interaction Between Calpain and Calpastatin 
Solving the calcium free structure of inactive calpain 2 aided in understanding the 
classical calpains. Calpains consist of a novel large subunit and in the case of the classical 
calpains heterodimerize with a common small subunit. The large subunit contains domains I-IV 
while the small subunit consists of domains V and VI (figure. 1.2). Domains I and II are similar 
to the papain like cysteine proteases and together form the active site cleft containing the catalytic 
triad Cysios, His262, and Asn286- The inactive calcium free crystal structure of calpain 2 shows this 
triad as unassembled. It is hypothesized that a conformational shift in response to calcium 
binding alters calpain to its active conformation and assembles the active site. Calpain domain III 
is a p-sandwich C2-like domain. C2 domains have been demonstrated to bind up to three calcium 
molecules. These calcium bind and neutralize the negatively charged aspartate residues in the 
acidic loops to aid in phospholipid binding (20). Domain V of the small subunit is a glycine rich 
hydrophobic domain that contains a segment that forms an oblique-oriented a-helix (12). These 
helices are amphipathic with a hydrophobic gradient that causes shallow embedding in 
membranes. Although this region is removed during autoproteolysis (10, 36) it may aid in 
localization prior to activation. Domain IV of the large subunit and domain VI of the small 
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Figure 1.2 Ribbon Diagram of the Calcium Free Recombinant Rat Calpain 2 Heterodimer 
The catalytic subunit consists of the amino-terminal helix (red), domain I (orange), domain II 
(yellow), domain III (green), the transducer region (blue), and domain IV (cyan). Domain V is 
not resolved by X-ray crystallography. The truncated small subunit shows domain VI (magenta). 
Domains I and II together form the active site cleft containing the unassembled catalytic triad 
Cysl05, His262, and Asn286. Diagram created via Pymol (DeLano Scientific LLC) using 
accession number 1U5I from structure resolved by Hosfield et al. (25). 
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subunit are homologous penta-EF hand domains. EF-hands are helix-loop-helix motifs that 
potentially bind one calcium molecule per loop when in the open form. The first four EF-hands 
of domain VI cooperatively bind three to four calcium molecules (56). EF-hands typically 
function in pairs. Thus the odd fifth EF-hand of domains IV and VI bind forming the major 
contacts between the two subunits of the heterodimer. This heterodimeric calpain structure is 
important for the binding of a calpastatin domain. 
Binding studies demonstrated that subdomain A of calpastatin binds domain IV of 
calpain's large subunit (64) and subdomain C binds domain VI of calpain's small subunit (42). 
CD spectra of synthetic nineteen residue peptides that mimic calpastatin domain I subdomain A 
and C indicated the peptides were not completely unstructured but "structurally primed" (42). 
This means they contain transient, unstable structure that readily transitions to full structure upon 
binding calpain. Subdomain A contains acidic residues mixed with hydrophobic residues on a 3-
4 period. Although calpastatin is intrinsically unstructured, this suggests subdomain A forms an 
amphipathic a-helix (64). The similarity between subdomains A and C implies they each bind 
calpain as an induced amphipathic a-helix (42). 
The crystal structure of the calcium bound calpain domain VI homodimer in the presence 
of a subdomain C peptide mimic shows subdomain C bound in two hydrophobic pockets (figure. 
1.3). These pockets are made up of helices El, Fl, and F2E3 of the first and part of the second 
and third EF hands in calpain domain VI. Specifically, calpastatin Leu235 and Phe239 are the key 
residues that bury into the two hydrophobic pockets exposed upon the activating conformational 
shift in calpain (figure 1.4). The smaller pocket opens due to a shift in calpain domain VI Leuio2 
and Trpi66- Calpastatin Phe239 forms van der Waals interactions with calpain Hisi29 and Glni73. 
The second larger hydrophobic pocket opens upon a shift in Glni73 while Hisi29 binds calpastatin 
Ser236. Calpain domain VI Trpi66 ends up sandwiched between calpastatin 
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Figure 1.3 Ribbon Diagram of Calpain Domain VI Homodimer Bound by Calpastatin C 
Peptide Mimic in the Presence of Calcium 
The penta-EF hand domain VI of the porcine calpain small subunit (green and cyan) forms a 
homodimer in the presence and absence of calcium. Each calpain domain is bound by four 
calcium molecules (yellow spheres) and one 19 residue synthetic peptide mimic of calpastatin 
domain I subdomain C (red and purple). Diagram created via Pymol (DeLano Scientific LLC) 
using accession number 1NX1 from structure resolved by Todd et al. (56). 
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Figure 1.4 Binding Interactions of Calpastatin C Peptide Mimic with Calpain Domain VI 
The specific amino acid residues of calpastatin subdomain C based synthetic peptide (red) 
contacting calpain domain VI (blue) in the presence of calcium. A) Calpain Glni73 shifts opening 
a large hydrophobic pocket where calpastatin Phe239 binds. Calpastatin Phe239 forms van der 
Waals interactions with calpain Glni73 and Hisi29 while calpastatin Ser236 interacts with calpain 
Hisng. Calpain Leui02, Leu]06, and Phei62 form a small hydrophobic pocket where calpastatin 
Leu235 binds. B) Calpastatin residues Phe239 and Leu235 bound in the two hydrophobic pockets on 
calpain, sandwich the calpain residue Trpi66- Diagram created via Pymol (DeLano Scientific 
LLC) using accession number 1NX1 from structure resolved by Todd et al. (56). 
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Leu235 and Phe6io- Thus Leu235, Ser236, and Phe239 of calpastatin subdomain C are the residues 
responsible for the major contacts to calpain domain VI. The homology between calpastatin 
subdomains A and C as well as calpain domains IV and VI allows this crystal structure to serve as 
a model for the structure of calpastatin domain I subdomains A and C bound to calpain domains 
IV and VI. 
Rationale and Design of Sensors to Detect Active Calpain 
The calpain-calpastatin binding interaction provided a basis for developing a sensor to 
detect active calpain utilizing fluorescence resonance energy transfer (FRET). FRET is the 
measure of energy transfer from a donor fluorophore to an acceptor fluorophore (33). In order for 
energy transfer to occur there must be 1) spectral overlap, 2) close proximity /location, and 3) 
proper orientation between a fluorophore pair. The pair of fluorophores must exhibit an overlap 
of the donor fluorophore's emission spectra and the acceptor fluorophore's excitation spectra. 
Upon excitation of the donor fluorophore, an acceptor fluorophore within 60 to 100 A will absorb 
the energy from the donor. The distance at which a fluorophore pair demonstrates 50% transfer 
efficiency is known as the Forster radius (Ro). The transfer of energy generates a shift in 
emission from primarily donor emission to acceptor emission at a longer wavelength. The 
fluorophore pair must also be in a parallel orientation to allow this energy transfer. A 
perpendicular orientation results in an orientation factor (K2) of zero, which would produce a zero 
rate of transfer between a fluorophore pair (33). 
The representative structure of calpastatin subdomains A and C bound to calpain domains 
IV and VI predicts the carboxy-terminus of calpain domain IV and the amino-terminus of 
calpastatin domain I are approximately 31 A apart (figure 1.3). Additionally, the amino-terminus 
of subdomain A and carboxy-terminus of subdomain C are predicted to be approximately 50 A 
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apart when bound to calpain. Both of these distances should allow FRET between a fiuorophore 
pair. These predicted distances were the basis for two different designs of a FRET based sensor 
to detect active calpain. The first design places the donor fluorophores FlAsH (Lumio Green) and 
eGFP at the carboxy-terminus of the large subunit of calpain 2 and the acceptor fluorophores 
tetramethylrhodamine (TMR) and Alexa Fluor 546 (AF546) at the amino-terminus of calpastatin 
domain I. Calcium dependent binding of acceptor-calpastatin domain I to donor-calpain 2 is 
predicted to bring the fiuorophore pair within ~31 A to generate FRET. The second design places 
the donor fiuorophore Alexa Fluor 568 (AF568) at the carboxy-terminus of a calpastatin domain I 
subdomain C peptide and the acceptor fiuorophore Alexa Flour 647 (AF647) at the amino-
terminus of a calpastatin domain I subdomain A peptide. In this design calcium induced binding 
of the fiuorophore modified calpastatin peptides to calpain is predicted to bring the fiuorophore 
pairs within -50 A. The closer distance of the fiuorophore pair in the first design is advantageous 
for producing a more robust FRET signal. The second design, however has the potential to detect 
endogenous calpain. Exploitation of the calpastatin-calpain binding interaction allows both 
designs to distinguish the active conformation of the classical calpains from inactive. 
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Chapter 2 MATERIALS AND METHODS 
Materials 
Tetramethylrhodamine-5-maleimide, Alexa Fluor 546-5-maleimide, Alexa Fluor 568-5-
maleimide, Alexa Fluor 647-2-maleimide were from Molecular Probes/Invitrogen. Lumio Green 
(FlAsH) was from Invitrogen. Quik Change XL II Site Directed Mutagenesis Kit and 
components were from Stratagene. Human calpastatin pIND(SPl)/V5-His C was a gift from Dr. 
Masatoshi Maki (Nagoya University, Japan) and Dr. Ronald Mellgren (Medical College of Ohio) 
(24, 34). pBlueScript (pBS) and pET24a plasmids were from Novagen. The pEGFP plasmid was 
from Clontech. Plasmids containing cDNA encoding rat calpain 2 CI05A in pET24 and 
truncated rat small subunit in pACpET were from Dr. John Elce (Queens University, Ontario). 
Porcine erythrocyte calpain 1 was purchased from Calbiochem. Restriction enzymes were from 
New England Biolabs or Invitrogen (NotI and Hindlll). T4 DNA ligase was from Promega. 
Ethane-dithiol and most other reagents were from Sigma-Aldrich. 
Subcloning and Mutagenesis of Calpastatin Domain I 
The full length human calpastatin sequence was amplified from the human calpastatin 
pIND(SPl)/V5-His C plasmid by PCR using a primer pair that flanked the EcoRI site of the 
vector (table 2.1, #1). The full length human calpastatin polymerase chain reaction (PCR) 
product was digested with EcoRI and inserted into the EcoRI site of pBS (figure 2.1 A). The 
human calpastatin pBS plasmid was transformed into XLlBlue competent cells. Calpastatin 
Domain I (encoding Valn4 to Ser27o as numbered in whole calpastatin) was amplified by PCR 
from calpastatin cDNA in pBS using primers to add a 5' Ndel site and 3' EcoRI site flanking the 
calpastatin domain I sequence (table 2.1, #2). This PCR product was digested with Ndel and 
EcoRI and ligated into pET24a at the Ndel and EcoRI sites. Four base pairs of the pET24 Sail 
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Primer Sequences 
5'-GCTCGGATCCACTAGTCCAG-3' 
5'-GCCACTGTGCTGGATATCTG-3' 
5 '-CGATACCGGCTGCATATGGTTGCTGGTATCACTGC A ATATC-3' 
5 '-GCCTGAGAATTCACTTCTGACTGTCCCTGCT-3' 
5 ' -A G TG A A TTC G A G C TC C A A C A A G C TTG C G G C C -3 ' 
5 ' -GAAGTCACAATTCCTAGAATTCGAGCTCCACAAGC-3 ' 
5 '-TCATCTGACTTCACCAGTGGGTCGCCTACAG-3' 
5 '-GCTGTGCCAGTTGAATGTAA ACCGGATAAACCATCG-3' 
5'-TCTAAACCGGATAAACCATGCGGAAAGTCAGGCATGGATG-3' 
5 '-GGATAAACCATCGGGAAAGTGTGGCATGGATGCTGCTTTGG-3' 
5 '-GCTATAGACGCCTTGTCATGTGACTTCACCAGTGGG-3' 
5'-CACCAGTGGGTCGCCTACATGTGCTGGAAAGAAAACTG-3' 
5'-GAAAACTGAAAAAGAGGAATGTACAGAAGTTTTAAAAGCTCAGTCAGC-3' 
5'-CCTCCAAAATATAGGGAACATATGGCTAAAAAGGAAGGGATCACAGG-3' 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
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Table 2.1 Primers for Calpastatin Subcloning and Mutagenesis 
Primer pairs used for amplification by PCR of (1) full length human calpastatin or (2) calpastatin 
domain I adding 5' Ndel and 3' EcoRI restriction sites. Restriction sites are underlined. The 
sense strand of the mutagenic primer pairs used to delete (3) 4 bp (bp 181-184) in the pET24a 
multiple cloning site to shift the His-tag in frame and (4) 204 bp of the 3' end of calpastatin 
domain I to create subdomain A constructs (A). The sense strand of the mutagenic primer pairs 
used to change codons (5) C24iS TGT-+AGT, (6) S142C TCT^TGT, (7) S148C TCG^TGC, (8) 
SisiC TCA^TGT, (9) S237C TCT->TGT, (10) A246C GCT—TGT and (11) S256C TCT^TGT. 
(12) The sense strand of the mutagenic primer pair used that changed 3 bp (TAT-»ATA) to create 
an Ndel site in calpastatin domain I. Mutated codons are marked blue in primer sequence. 
13 
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Figure 2.1 Diagram ofSubcloning Strategy for Calpastatin Peptide Variants 
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site (bp 181-184) were deleted to put the His-tag in frame (table 2.1, #3). Four mutations were 
introduced into calpastatin domain I using the Quik Change II XL Site Directed Mutagenesis Kit 
and transformed into XLlOGold ultracompetent cells (Stratagene) (table 2.1, #5-8) (figure 2.1 A 
& B). These mutations included: C24iS (TGT-»AGT), S142C (TCT^TGT), S148C (TCG^TGC), 
and S151C (TCA—>TGT). The resulting four constructs containing variants of the calpastatin 
domain I sequence were designated by their new residues S241, C142S241, C148S241, or Q51S241. 
Subcloning and Mutagenesis of Calpastatin Domain I Subdomains A and C 
Calpastatin domain I subdomain C sequence (Pro2o3 to Ser27o) was deleted using Quik 
Change mutagenesis to leave the calpastatin domain I subdomain A sequence encoding Valiu to 
Pro202 (table 2.1, #4). This deletion was performed in each of the four calpastatin domain I 
constructs to create four calpastatin domain I subdomain A constructs (figure 2.1 B). Changing 
three base pairs (TAT-»ATA) by site directed mutagenesis created a new internal Ndel site in the 
calpastatin domain I S241 and C24i sequences (table 2.1, #12) (figure 2.1 C). Digestion with Ndel 
removed the region encoding Valn4 to Leu2o9- Religation created two calpastatin domain I 
subdomain C constructs S241 and C241 (encoding Ala2io to Ser27o). Using calpastatin domain I 
subdomain C S24i as template, codons for S237C (TCT—>TGT), A246C (GCT—»TGT) and S256C 
(TCT—>TGT) were individually mutated by Quik Change mutagenesis (table 2-1, #9-11). The 
five constructs containing the calpastatin domain I subdomain C sequence are designated by their 
new residues S24i, C237S241, S24iC246, and S241C256 or by the WT codon C24i. 
Mutagenesis ofCalpain 2 Large Subunit and Creation of eGFP Fusion Protein 
Thirteen base pairs of the pET24d multiple cloning site in the rat calpain 2 CI 05 A pET24 
plasmid were deleted to allow synthesis of the plasmid encoded carboxy-terminal His-tag (table 
2.2, #1). The sequence encoding the tetra-cys motif (ACCPGCCA) was inserted at the 3' end of 
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calpain 2 C105A cDNA by Quik Change mutagenesis (table 2.2, #2). The DNA encoding eGFP 
was digested from the pEGFP vector using Hindlll and Notl. The eGFP sequence was ligated 
into the Hindlll and Notl sites between the sequence encoding calpain 2 C105A and the Hexa-His 
tag of the pET24 plasmid. Insertion of two base pairs (GG) before the eGFP stop codon allowed 
synthesis of calpain-eGFP including a carboxy-terminal His-tag (table 2.2, #3). 
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Primer Sequences 
5 ' -GCTGAGTTTTTCAGTACTCCTGAAAGCTTGCGGCC-3 ' 
5 '-GCCGCACTCGAGGCCTGCTGCCCCGGGTGCTGCGCCCACCACCACCAC-3' 
5'-CGAGCTGTACAAGGGTAAAGCGGCCGCAC-3' 
1 
2 
3 
Table 2-2 Primers for Calpain 2 Mutagenesis 
(1) The sense strand of the mutagenic primer pair used to delete 13 bp (A) of 3' sequence between 
calpain 2 C105A coding sequence and pET24 vector to remove a stop codon and shift the vector 
encoded His-tag into frame. (2) The sense strand of the mutagenic primer pair used to insert 24 
bp (blue) encoding the tetra-cysteine motif between the vector multiple cloning site and His-tag 
of the construct containing calpain 2 C105A large subunit. (3) The sense strand of the mutagenic 
primer pair used to insert 2 bp (blue) to shift the eGFP stop codon out of frame and pET24 His-
tag in frame in calpain 2 CiosA-eGFP construct. 
Expression of Calpain and Calpastatin Constructs 
All calpastatin constructs were transformed into Escherichia coli strain BL21(DE3) 
competent cells (Novagen); the calpain 2 constructs were co-transformed with the plasmid 
encoding truncated rat recombinant small subunit in a modified pET vector designated pACpET 
(15). Transformed cells were selected on Luria broth (LB)-agar plates (1.6%) containing either 
kanamycin (10 ug/mL, calpastatin) or kanamycin (10 ug/mL) and ampicillin (50 ug/mL, calpain) 
at 37°C for 16-18 hours (overnight (O/N)). Isolated colonies were used to inoculate LB with 
either kanamycin (50 ug/mL, calpastatin) or kanamycin (50 ug/mL) and ampicillin (100 ug/mL, 
calpain) and incubated shaking at 250 rpm at 37°C O/N. Permanent cell stocks were stored in 
50% media and 25% glycerol at -80°C. LB with selective antibiotics was inoculated with mature 
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culture (8.5 fold dilution) and incubated shaking at 37°C to an optical density of 0.8-1.0 at 600 
nm. The transformed cells were induced to express protein or peptide using isopropyl-beta-D-
thiogalactopyranoside (IPTG) (0.5 mM) and incubated shaking (200-250 rpm) at room 
temperature (RT) O/N. The cells were centrifuged (CF) at 4°C 15 minutes in a JLA10.5 rotor at 
4,000 rpm, washed in 0.15 M NaCl and CF at 4°C, 15 minutes using a JA25.5 rotor at 5,000 rpm. 
The supernatant was aspirated and the wet cell pellets were stored at -80°C. 
Purification of Recombinant Expressed Calpastatin Peptides 
Cell pellets were resuspended in 25 mM 4-morpholinepropanesulfonic acid (MOPS) pH 
8.0, 10 mM imidazole, 0.10 M sodium chloride (NaCl), 0.4 mM ethylene glycol bis(2-aminoethyl 
ether)-N,N,N'N'-tetraacetic acid (EGTA), 0.2 mM ethylenediaminetetraacetic acid (EDTA), 0.1 
mM (3-mercaptoethanol (p-ME) (Ni Binding Buffer (NiBB)) (0.1-0.16 g wet cell weight per mL); 
subjected to three freeze-thaw cycles (-80°C to RT) and CF at 4°C for 20 minutes in a JA25.5 
rotor at 17,000 rpm. The supernatant was passed through Ni-NTA agarose resin (Qiagen) 
previously packed and equilibrated in NiBB at 4°C with a flow rate of ~8 sec/drop. The resin 
was washed with NiBB prior to elution of bound peptide with 100 mM imidazole in NiBB, and a 
second elution with 250 mM imidazole in NiBB (Ni Elution Buffer (NiEB)). The protein 
concentration was monitored using Bradford reagent (Biorad). The eluted protein was pooled and 
dialyzed against 50 mM 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES) pH 7.0, 
1 mM tris (carboxyethyl) phoshine (TCEP) and stored at -20°C. 
Fluorogenic Modification of Calpastatin Peptides 
The calpastatin peptides were labeled according to the protocol in the Thiol-Reactive 
Probes manual from Molecular Probes/Invitrogen. Tetramethylrhodamine-5-maleimide (TMR), 
Alexa Fluor 546-5-maleimide, Alexa Fluor 568-5-maleimide, or Alexa Fluor 647-2-maleimide 
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were resuspended in dimethylsulfoxide (DMSO) to 10.4 mM. Stirring at RT, a 13 fold molar 
excess of fluorophore was added dropwise to calpastatin peptide (40-80 uM) in 50 mM HEPES 
pH 7.0, 1 mM TCEP. The reaction was incubated at RT for 1 hour. A 5 molar excess of B-ME to 
total fluorophore was added to stop the reaction by reacting with unbound fluorophore. 
Fluorophore labeled peptide was dialyzed extensively against 25 mM MOPS pH 7.5 using Tube-
O-Dialyzers (4000 or 8000 MWCO tube-O-dialyzers, Genotech). The stoichiometry of 
fluorogenic modification was determined using equation (2.1): 
f/p = A (2.1) 
e(CP) 
where f/p is the ratio of fluorophore per peptide, A is the fluorophore absorbance at fluorophore's 
absorbance wavelength, £ is the fluorophore's extinction coefficient (cm"1 M"1), and Cp is the 
peptide molar concentration. Extinction coefficients used were 95,000 cm"1 M"1 for TMR at 541 
nm, 93,000 cm"1 M"1 for Alexa Fluor 546 at 554 nm, 92,000 cm"1 M"1 for Alexa Fluor 568 at 575 
nm or 265,000 cm"1 M'1 for Alexa Fluor 647 at 651 nm (Molecular Probes-Stratagene). Peptides 
labeled with fluorophore were stored at -80°C. 
Purification ofCalpain 2 Cw$A 
Escherichia coli strain BL21(DE3) cells previously induced to co-express the small 
subunit construct and one of the constructs containing calpain 2 C105A were resuspended in 50 
mM MOPS pH 7.5, 10 mM EGTA, 10 mM EDTA, 10 mM B-ME (0.12-0.24 g wet cell weight 
per mL). Phenylmethylsulfonyl fluoride (PMSF) was added to the cell suspension (50 ug/mL) 
and cells were lysed by sonication (Branson Sonifier 450), on ice, for 6-8 minutes (duty cycle 50-
60, output 6). The soluble proteins were recovered as supernatant following centrifugation at 4°C 
for 20 minutes with a JA25.5 rotor at 17,000 rpm. The supernatant was applied to DEAE 
Sephacel resin previously packed and equilibrated in 50 mM MOPS pH 7.5, 2 mM EGTA, 2 mM 
EDTA, 5 mM B-ME (DEAE Binding Buffer (DEAE BB)) at 4°C with a flow rate of ~3 sec/drop. 
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The DEAE resin was washed with DEAE BB followed by 0.15 M NaCl in DEAE BB. The 
bound calpain was eluted using 50 mM MOPS pH 7.0, 0.5 M NaCl, 2 mM EGTA, 2 mM EDTA, 
5 mM (3-ME (DEAE Elution Buffer (DEAE EB)). The DEAE eluted protein was pooled and 
chromatographed on Reactive Red Agarose (RRA) resin previously packed and equilibrated in 
DEAE EB at 4°C with a flow rate of ~3 sec/drop. The RRA resin was washed with DEAE EB 
while maintaining the same flow rate. The bound protein was eluted using cold deionized 
distilled water (8 sec/drop flow rate). The calpain was eluted from RRA into tubes containing 
concentrated NiBB (50 mM imidazole) for C105A H6 and C105A tetra-cys H6 or concentrated 
DEAE BB for Ci05A-eGFP. The eluted calpain diluted the NiBB (5 mM imidazole) and DEAE 
BB to concentrations specified above. Calpain C105A H6 and C105A tetra-cys H6 in NiBB were 
bound to Ni-NTA agarose resin previously packed and equilibrated in NiBB at 4°C with a flow 
rate of ~8 sec/drop. The bound C105A H6 and C105A tetra-cys H6 were washed with NiBB and 
eluted with NiEB. The CiosA-eGFP in DEAE BB was bound to DEAE Sephacel resin packed 
and equilibrated in DEAE BB at 4°C with a flow rate of ~3 sec/drop. The bound protein was 
washed with DEAE BB then eluted with DEAE EB. The protein concentration was monitored 
using Bradford reagent (Biorad). Purified C105A H6 and partially purified CiosA-eGFP were 
dialyzed against 50 mM MOPS pH 7.5, 1 mM EGTA, 1 mM EDTA, 0.5 mM dithiothreitol 
(DTT). Purified d05A tetra-cys H6 was dialyzed against 50 mM MOPS pH 7.5, 1 mM TCEP. 
Aliquots of purified calpains were flash frozen using liquid nitrogen, and stored at -80°C. 
Preparation of Calpain 2-eGFP Crude Lysates 
A pellet of BL21(DE3) cells that were induced to co-express the small subunit construct 
and the construct containing calpain 2 CiosA-eGFP was resuspended, sonicated, and centrifuged 
as explained for calpain purification above. Total protein was quantified using Bradford reagent. 
The concentration of CiosA-eGFP was determined by absorbance at 508 nm using the eGFP 
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extinction coefficient of 55,900 cm"1 M"1. Aliquots of crude lysates were flash frozen using liquid 
nitrogen and stored at -80°C. 
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was executed according to Schagger and von Jagow (48). Following 
electrophoresis gels were soaked in fixative reagent (50% methanol, 10% acetic acid); stain 
(0.1% Coomassie, 0.05% amido black, 40% methanol, 10% acetic acid); destain (25% methanol, 
10% acetic acid) until the background was clear and stored in distilled deionized water. Images 
of gels were recorded using the Chemilmager 4400 Low Light Imaging System (Alpha Innotech 
Corporation). 
Fluorogenic Modification of Calpain 2 C105A Tetra-Cys 
A working solution of 1 mM FlAsH (Lumio Green, Invitrogen), 10 mM EDT, 92% 
DMSO was prepared immediately prior to use. FlAsH working solution was added to purified 
calpain 2 Ci05A tetra-cys H6 in 50 mM MOPS pH 7.5, 1 mM TCEP at a ratio of 2 moles of 
FlAsH per mole of calpain and incubated at 4°C O/N (1% DMSO). The FlAsH labeled calpain 
was dialyzed extensively against 50 mM MOPS pH 7.5, 1 mM EGTA, 1 mM EDTA, 0.5 mM 
DTT. The stoichiometry of fluorogenic modification was determined using equation (2.1) and 
the FlAsH extinction coefficient of 41,000 cm"1 M"1 at 508 nm. The calpain concentration was 
estimated using the absorbance at 280 nm and the extinction coefficient 117,160 cm"1 M"1. 
Aliquots of ClosA-FlAsH were flash frozen using liquid nitrogen, and stored at -80°C. 
Measuring FRET in Response to Increasing Acceptor-Calpastatin 
Initial donor emission CIOSA-FIASH (2 uM) or CiosA-eGFP (1 uM) was established in the 
absence of acceptor-calpastatin by exciting at 460 (CiosA-FlAsH) or 440 nm (CiosA-eGFP) nm 
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while scanning for emission between 480 (or 495) to 650 nm using a Perkin-Elmer luminescence 
spectrometer LS 50 B (4.0-5.0 nm slits). Emission scans were performed following addition of 1) 
acceptor labeled calpastatin domain I (1 uM), 2) calcium (8-10 mM), 3) additional aliquots of 
acceptor-calpastatin domain I (up to 6 uM (Ci05A-FlAsH) or 12 uM (Ci05A-eGFP)), and 4) 
EGTA (18-20 mM) to show reversal of binding. Five scans were performed after each addition. 
Data from the five scans were averaged (using MatLab) and the areas under the donor (510-545 
nm, FlAsH; 480-540 nm, eGFP) and acceptor (560-620 nm, FlAsH-TMR; 550-620 nm, eGFP-
AF546) emission peaks was calculated according to equation (2.2): 
A = S y (2.2) 
where A is the area and y is the fluorescence intensity between the designated wavelengths (at 0.5 
nm intervals). 
Measuring FRET in Response to Increasing Calcium 
Initial donor emission Ci05A-FlAsH (0.75 uM) or Ci05A-eGFP (1 uM) in 50 mM MOPS 
pH 7.5, 0.25 M NaCl, 1 mM TCEP was established in the absence of acceptor-calpastatin by 
exciting at 460 nm while scanning for emission between 480 (or 495) to 650 nm (4.0-5.0 nm 
slits). Emission scans were performed following addition of 1) acceptor-calpastatin domain I 
(1.5-2 uM), 2) calcium (up to 2 mM), and 3) EGTA (12 mM) to show reversal of binding. Five 
scans were performed after each addition. Data from the five scans were averaged (using 
MatLab) and the ratio of RFU at the acceptor emission peak (TMR or Alexa Fluor 546, 570 nm) 
over RFU of the donor emission peak (eGFP, 508 nm; FlAsH 528 nm) (EmA/EmD) was 
calculated. The free calcium concentrations for each data collection point were calculated via 
WEBMAXC Standard available through Maxchelator. The EmA/EmD ratios were plotted vs. the 
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free calcium concentration. The percent increase in the calcium dependent signal was calculated 
using equation (2.3), 
% increase = /_RrRi_V 100) (2.3) 
w 
where R; is the EmA/EmD ratio at 0 uM free calcium and Rf is the average EmA/EmD ratio at 0.8-2 
mM free calcium (saturation). The increase in ratio for the amino-terminally labeled acceptor-
calpastatin peptides or nonspecifically labeled acceptor-peptides were averaged for each donor-
calpain and expressed as an average percent ± the average difference. 
Measuring FRET in Response to Binding of Fluorogenic Calpastatin Subdomain 
Peptides to Calpain 
Initial donor emission of calpastatin domain I subdomain C-AF568 (0.5 uM) in 50 mM 
MOPS pH 7.5, 0.25 M NaCl, 1 mM TCEP and calpain 2 C105A (1 uM) was established by 
exciting at 515 nm while scanning for emission between 570 to 720 nm. Emission scans were 
performed following addition of 1) calpastatin domain I subdomain A-AF647 (2 uM), 2) calcium 
(11 mM), and 3) EGTA (22 mM) to show reversal of binding. Five scans were performed after 
each addition using 2.5 nm excitation slits and 5.0 nm emission slits. The five scans were 
averaged (using MatLab) and the ratio of RFU at the acceptor emission peak (AF647 665 nm) 
over RFU of the donor emission peak (AF568 594 nm) (EmA/EmD) was calculated. The percent 
increase in the calcium dependent signal was calculated according to equation (2.3). 
Measuring FRET in Response to Unmodified Calpastatin, Calpains, or Calpain 
Substrates 
Initial donor emission C105A-eGFP (1 uM) in 50 mM MOPS pH 7.5, 0.25 M NaCl, 1 mM 
TCEP was established in the absence of acceptor-calpastatin by exciting at 460 nm while 
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scanning for emission between 480 to 650 ran using 4.8 (Pi integrin & a-casein) or 5.0 
(calpastatin) nm slits. Emission scans were performed following addition of 1) calpastatin 
domain I Ci48S24i-AF546 (1 uM) with calpastatin domain I S241 (0-2 uM), pi integrin 
cytoplasmic tail (0-20 pM) or a-casein (0-20 uM), 2) calcium (10 mM), and 3) EGTA (20 mM) 
to show reversal of binding. In a similar series of assays, the initial donor emission CiosA-eGFP 
(0.5-1 uM) with calpain 1 (0-1 uM) or calpain 2 Ci05A H6 (0-2 uM) in 50 mM MOPS pH 7.5, 
0.25 M NaCl, 1 mM TCEP was established in the absence of acceptor-calpastatin by exciting at 
460 nm while scanning for emission between 480 to 650 nm using 5.0 (calpain 2) or 8.0 (calpain 
1) nm slits. Emission scans were performed following addition of 1) calpastatin domain I 
Ci48S24i-AF546 (0.5-1 uM), 2) calcium (10 mM), and 3) EGTA (20 mM) to show reversal of 
binding. Five scans were performed after each addition. The data from the five scans were 
analyzed as previously described on pg 21. 
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Chapter 3 RESULTS 
Constructing Fluorogenic Proteins 
Subdoning and Mutagenesis of Calpastatin Peptides In an initial strategy to develop a FRET 
sensor for detecting active calpain, calpastatin was modified to allow specific labeling with 
acceptor fluorophores. Calpastatin domain I was chosen for use based on the premise that one 
inhibitory domain binds and inhibits one molecule of calpain. Specifically domain I was chosen 
due to its relative effectiveness inhibiting calpains 1 and 2 (I>IV>III>II) (27). The chemistry of 
maleimide coupling to thiol groups allows specific modification of cysteine residues when using 
maleimide conjugated fluorophores. To employ these fluorophores and specifically modify the 
amino-terminus of calpastatin domain I, constructs expressing calpastatin domain I with a single, 
distinctly located cysteine residue near the amino-terminus were engineered. Calpastatin domain 
I, Valn4 to Ser27o (numbering as in whole calpastatin), was subcloned from full length human 
calpastatin into the pET24a expression vector. Naturally occurring domain I contains one 
cysteine residue at position 241 (C241) (figure 3.1). To allow specific labeling near the amino-
terminus of calpastatin domain I, cysteine 241 was first mutated to encode a serine. Using this 
cysteine free construct, three amino-terminal serine residues at positions 142, 148, and 151 were 
individually changed to cysteines. The four different calpastatin domain I constructs generated 
include three constructs each encoding one, distinct amino-terminally located cysteine residue 
S142C C241S, Si4gC C241S, or S151C C241S and one control construct encoding no cysteine residues 
C241S. These constructs and the peptides expressed from them are designated by the new residues 
S24I, C142S241, C148S241, Or Ci5iS241-
25 
114 
142 148 151 
i 1 I 
V A G I T A I S G K P G D K K K E K K S L T P A V P V E S K P D K P S G K S G 152 
15 3 M D A A L D D L I D T L G G P E E T E E E N T T Y T G P E V S D P M S S T Y I 19 1 
19 2 E E L G K R E V T IP~P~KYR^! L L A K KEG I T G P PADS S K P I G P D D 130 
132 A I D A L S S D F T C G S P T A A G K K T E K E E S T E V L K A Q S A G T V R S 270 
t t T " t 
237 241 246 256 
Figure 3.1 Human Calpastatin Domain 1 Peptide Sequence 
Human calpastatin domain 1 amino acid sequence as numbered from whole calpastatin. The 
amino acid residues altered by site directed mutagenesis are shown in blue and numbered. 
Calpastatin domain I subdomain A peptides consisted of residues 114 to 202 (red underlined) and 
calpastatin domain I subdomain C peptides consisted of residues 210 to 270 (green underlined). 
The key inhibitory sequence of the subdomain B peptide mimics is overlined (grey). Calpastatin 
domain I and subdomain A peptides are expressed with a Met before Vn4 while calpastatin 
domain I subdomain C peptides are expressed with a Met before A2io-
In an alternative strategy to develop a FRET sensor for detecting active unmodified 
calpain, constructs to express calpastatin domain I subdomain A and subdomain C peptides were 
created and modified to allow specific labeling with maleimide fluorophores. To develop the 
constructs expressing calpastatin domain I subdomain A, the four calpastatin domain I constructs 
S241, C142S241, C148S241, and Ci51S24i were used as templates for mutagenesis to delete the 3' 
carboxy-terminal sequence encoding Pro2o3 to Ser27o. This resulted in three calpastatin domain I 
subdomain A constructs each encoding one distinctly located amino-terminal cysteine residue and 
one construct encoding no cysteine residues (figure 3.1). To generate constructs expressing 
calpastatin domain I subdomain C, mutagenesis introduced a new internal Ndel site in the 
constructs containing calpastatin domain I C241 or S241. Subsequent digestion with Ndel and 
religation allowed removal of the sequence encoding Valn4 to Leu209- This produced constructs 
expressing calpastatin domain I subdomain C encoding the naturally occurring (WT) cysteine 
residue at position 241 (C24i) or encoding no cysteine residues (S24i)- Serine 237, alanine 246, or 
serine 256 were mutated to cysteines in calpastatin domain I subdomain C S24i. Thus there are 
four calpastatin domain I subdomain C constructs each encoding one distinctly located cysteine 
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residue; S237C C24iS, C241, C241S S246C, and C241S S256C (figure 3.1). These constructs are 
designated by either their new codons C237S241, S241C246, and S241C256 or by the WT codon C241. 
Purification and Fluorogenic Modification of Calpastatin Peptides The four calpastatin 
domain I constructs, four calpastatin domain I subdomain A constructs and four calpastatin 
domain I subdomain C constructs were each expressed in the BL21(DE3) Escherichia coli (E. 
colx) expression strain. After induction of expression by IPTG, cells resuspended in buffer (see 
methods) were subjected to three cycles of being frozen at -80°C and then thawed at room 
temperature. This exploited the expressed peptides' small size to be released from the cells with 
minimal cell lysis. Comparing the supernatant released from these cells after being repeatedly 
frozen and thawed (S) to the protein contents remaining in the cells (L) demonstrated release of 
small peptides in the supernatant (figure 3.2 A). The peptides were purified utilizing the 
expressed peptides' carboxy-terminal hexa-histidine affinity tag to bind Ni agarose under native 
conditions. This produced relatively pure peptides with the theoretical molecular weight of 
approximately 18.7 kDa for domain I (figure 3.2), 11.7 kDa for subdomain A, or 8.4 kDa for 
subdomain C (figure 3.2 B). The purified calpastatin peptides however did not migrate true to 
their size but appeared larger (-27 kDa for domain I, —17 kDa for subdomain A, or -12 kDa for 
subdomain C) than the theoretical molecular weight on the SDS polyacrylamide gels. This 
phenomenon is characteristic of intrinsically unstructured proteins and intact calpastatin (54) 
further supporting successful purification of the engineered calpastatin peptides. 
Using the specificity of maleimide's reactivity with thiol groups and the lone cysteines 
specifically engineered in the peptides the four purified domain I peptides were labeled with 
tetramethylrhodamine (TMR)-5-maleimide or Alexa Fluor 546 (AF546)-5-maleimide. The four 
purified subdomain A peptides were labeled with Alexa Fluor 647 (AF647)-2-maleimide or 
Alexa Fluor 546-5-maleimide and the four purified subdomain C peptides were labeled with 
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Figure 3.2 SDS-Polyacrylamide Gel Electrophoresis of Recombinant Calpastatin Peptides 
A) E. coli expressing recombinant human calpastatin domain I S241 suspended in buffer were 
subjected to three freeze/thaw cycles. The supernatant was separated from the intact cells and 
loaded on Ni resin for purification under native conditions. To monitor progression of peptide 
isolation, aliquots at each stage of the purification procedure were treated with SDS sample buffer 
and analyzed by electrophoresis. Aliquots include lysate from cells post freeze/thaw (L), 
supernatant post freeze/thaw (S), Ni unbound (U), Ni elution (E) and Ni elution shoulder (Sh). 
Migration of molecular weight markers (Pharmacia) is indicated in kDa. The purification 
progress is representative for all calpastatin peptides purified. Bands corresponding to the 
calpastatin domain I peptide is marked by an arrow. B) Recombinant human calpastatin domain I 
subdomain A d 5 i (A) and subdomain C S241C256 (Q peptides (5 ug) were purified as described 
for domain I. Size and purity of purified subdomains shown are representative for the eight 
purified subdomain A and C peptides. Bands corresponding to calpastatin subdomain A and C 
peptides are marked with arrows. Migration of markers is indicated in kDa and based on a 
combination of low molecular weight markers (Pharmacia) and Protein Markers (USB). Gels 
pictured are 9% acrylamide and stained with Coomassie blue-amido black. 
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Alexa Fluor 568 (AF568)-5-maleimide or Alexa Fluor 546-5-maleimide (see methods). As 
shown in table 3-1 this created eight acceptor fluorophore labeled domain I peptides, eight 
acceptor labeled subdomain A peptides, four donor labeled and four acceptor labeled subdomain 
C peptides. 
The stoichiometry of the fluorophore labeled calpastatin peptides was determined to 
assess the extent of fluorophore modification. Stoichiometry was determined by comparing the 
estimated peptide concentration after labeling to the estimated concentration of the fluorophore. 
The fluorophores were quantified using published extinction coefficients. The calpastatin 
concentration post-labeling was estimated based on the concentration prior to labeling. Spectral 
overlap of the AF546 and TMR absorbance with the absorbance wavelength for the Bradford 
reagent prevented accurate quantification of acceptor-calpastatin. Quantification of the 
fluorophores using extinction coefficients is more accurate than quantification of calpastatin by 
Bradford and enhanced BCA assays (11). The stoichiometry of fluorophore per estimated mole 
of cysteine containing peptide indicated a 2:1 to 4:1 ratio even though each peptide contained 
only one cysteine residue for modification. A ratio greater than 1:1 indicates that either the 
calpastatin peptide concentration is inaccurate or there is an occurrence of nonspecific coupling 
of fluorophore to residues other than cysteines. The combination of an accurate fluorophore 
quantity and potential underestimation of the calpastatin peptides could produce an inaccurate 
fluorophore to peptide ratio. However, nonspecific labeling by maleimide conjugated 
fluorophores has been reported (4, 51). To test for nonspecific modification calpastatin domain I 
S241 and subdomain A which both lack cysteine residues, were treated with TMR-5-maleimide 
and/or AF546-5-maleimide. Modification of both peptides by the maleimide fluorophores was 
observed. Specifically calpastatin domain I S2« was modified by TMR with a stoichiometry of 
approximately 0.5:1 (n=l). These observations confirm the occurrence of some nonspecific 
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Table 3-1 Compilation of Fluorogenic Proteins 
Full list of fluorogenic proteins developed and tested for FRET biosensors to detect active 
calpain. The calpastatin peptides are designated by their new residues. The control peptides are 
marked (*). 
30 
Cio5A-FlAsH 
Cio5A-eGFP 
Calpastatin Domain I Subdomain C C237S241-AF568 
Calpastatin Domain I Subdomain C C24i-AF568 
Calpastatin Domain I Subdomain C S241C246-AF568 
Calpastatin Domain I Subdomain C S24iC256-AF568 
Calpastatin Domain I S241-TMR* 
Calpastatin Domain I C142S241-TMR 
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labeling. The calpastatin domain I S241-AF546, domain I S241-TMR and subdomain A-AF546 
peptides served as controls for the nonspecific coupling of fluorophore to residues other than site 
specific cysteines in FRET assays. 
Generating Donor Modified Calpains Specific labeling of the carboxy-terminus of the large 
subunit of calpain 2 required a different strategy. FlAsH (Lumio Green-Invitrogen), a fluorescein 
modified with two arsenic groups, specifically binds a tetra-Cys motif (CCXXCC) (65). This rare 
motif is not found in native calpain 2. The sequence encoding ACCPGCCA was inserted by site 
directed mutagenesis 5' to the pET24 vector hexa-histidine tag at the carboxy-terminus of domain 
IV of the inactive calpain 2 mutant C105A and designated C105A tetra-cys (CiosA-4C). 
Alternatively, the sequence encoding eGFP was fused to the carboxy-terminus of calpain 2 C105A 
domain IV and designated CiosA-eGFP. Each of these constructs was co-expressed with a 
plasmid encoding the recombinant rat calpain small subunit in E. coli and purified as intact 
heterodimeric proteins (methods). The CiosA-eGFP subunits although only partially purified are 
evident by SDS-PAGE gel (figure 3.3). These consist of the 21 kDa small subunit and 109 kDa 
fusion protein of 80 kDa calpain 2 C105A large subunit and 29 kDa eGFP. The eGFP is separated 
from the calpain large subunit by a 20 residue linker region while a 7 residue linker separates 
eGFP from the pET24 vector encoded hexa-histidine tag. The 80 kDa large and 21 kDa small 
subunits of the purified C105A-4C can be distinguished on an SDS-PAGE gel (figure 3.3). FlAsH 
was bound to the tetra-cysteine motif of purified Q05A-4C as described in methods and 
redesignated CiosA-FlAsH. Fluorophore and calpain concentrations post-labeling were 
determined utilizing extinction coefficients for FlAsH at 508 nm and calpain at 280 nm 
absorbance. The stoichiometry of labeling was determined to range from 1:2 to 1:1 FlAsH per 
calpain based on these concentrations (n=3). Thus inactive calpain 2 labeled at the large subunit 
carboxy-terminus with two different donor fluorophores, FlAsH and eGFP, was generated. 
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Figure 3.3 SDS-Polyacrylamide Gel Electrophoresis of Recombinant Calpains 
Purified recombinant rat calpain 2 C105A (1), C105A tetra-cysteine (2) and partially purified C105A-
eGFP (3) (4 ug each). Bands corresponding to the calpain large (-80 or 109 kDa) and small (-21 
kDa) subunits are marked with arrows. Migration of molecular weight markers (Pharmacia) is 
indicated in kDa. Gel pictured is 9% acrylamide and stained with Coomassie blue-amido black. 
Demonstrating Calcium Dependent Detection of Calpain using FRET 
A Two Component Strategy for Detecting Active Calpain The two different designs of a 
sensor to detect active calpain both exploit the calcium dependent, specific binding of calpastatin 
to the conventional calpains. The two component strategy places the acceptor fluorophores 
AF546 or TMR at the amino-terminus of calpastatin domain I and the donor fluorophores FlAsH 
or eGFP at the carboxy-terminus of calpain 2 C105A domain IV. In the presence of calcium the 
acceptor-calpastatin is expected to bind donor-calpain bringing the fluorophore pair within 
approximately a 31 A distance. This distance should allow FRET between the fluorophore pair. 
Two different approaches were used in binding assays to test for a FRET generating pair of 
fluorogenic proteins. The initial approach was to add aliquots of acceptor-calpastatin domain I to 
1 or 2 uM donor-calpain in the presence of calcium. Using a donor specific excitation 
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wavelength (460 nm), changes in the donor and acceptor emission spectra (480 or 495 to 650 nm) 
were monitored as the acceptor-calpastatin concentration increased. Results representative for the 
twelve pairs are shown using an acceptor-calpastatin modified at an amino-terminal cysteine as 
acceptor to a donor-calpain (figure 3.4). The donor emission peak in these scans decreases and 
the acceptor emission peak increases as the acceptor-calpastatin domain I concentration increases. 
Both donor quenching and increasing acceptor emission are indicative of successful FRET. The 
most sensitive measure of FRET is expressed as a ratio of acceptor emission over donor emission 
(EmA/EmD). As expected the EmA/EmD increased in response to the increasing acceptor-
calpastatin but did not demonstrate saturation of binding to the limited amount of donor-calpain 
(figure 3.5). Direct excitation of the acceptor fluorophore or dilution of the donor fluorophore 
both may contribute to preventing saturation of the ratio. 
There are two components that contribute to the increase of the ratio; quenching of the 
donor emission and an increase in acceptor emission. Each addition of acceptor-calpastatin 
domain I dilutes the donor-calpain throughout the assay. This dilution may contribute to the 
apparent donor quenching. To determine the effect of dilution on the donor emission peak, the 
change in the area of the donor emission peak for control assays using unmodified calpastatin 
domain I S24i was compared to that of FRET assays using acceptor-calpastatin. The area of the 
FlAsH donor emission peak decreased 3.95±0.05 (n=2) in the presence of calpastatin domain I 
C151S241-TMR but only 1.01 (n=l) in the presence of unmodified calpastatin domain I S24i (0-10 
uM) (figure 3.6 A). The area of the eGFP donor emission peak decreased 4.86 (n=l) in the 
presence of calpastatin domain I Ci42S24i-AF546 but only 1.86±0.38 (n=2) in the presence of 
unmodified calpastatin domain I S24i (0-10 uM) (figure 3.6 B). These results demonstrate the 
area of the donor emission peaks decreased substantially in the presence of acceptor-calpastatin 
domain I. The area of the donor also decreased in the presence of unmodified domain I although 
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Figure 3.4 Representative Emission Scans of Donor-Calpains in the Presence of Increasing 
Concentrations ofAcceptor-Calpastatin 
Initial donor emission for A) Ci05A-FlAsH (2 uM) or B) CjosA-eGFP (1 uM) was established in 
the absence of acceptor-calpastatin by exciting at 460 nm (A) or 440 nm (B) while scanning for 
emission between 495 (A) or 480 (B) to 650 nm using 5.0 nm slits. Emission scans were 
performed following addition of 1) calpastatin domain I C151S241-TMR (1 uM), 2) calcium (14 
mM), 3) additional aliquots of calpastatin domain I Ci5iS24i-TMR (2-10 uM), and 4) EGTA (21 
mM) to show reversal of binding. Insets designate individual scans for each step in the binding 
assays. Results in each panel are representative for the six different acceptor modified calpastatin 
peptides studied. 
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Figure 3.5 FRET Response Relative to the Concentration ofAcceptor-Calpastatin Peptide 
The ratio of acceptor emission over donor emission was used to assess FRET relative to acceptor-
calpastatin concentration for a series of binding assays. Using data from assays similar to those 
in figure 3.4, the EmA/EmD ratio was determined for A) CiosA-FlAsH (575 nm/528 nm) or B) 
ClosA-eGFP (575 nm/508 nm) as donor to one of the six acceptor-calpastatin domain I peptides in 
the presence of calcium. Insets designate symbols for the different acceptor-calpastatin domain I 
peptides. Results shown are representative of two assays unless otherwise indicated (1) in insets. 
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Figure 3.6 Controls for Dilution and Direct Excitation Effects 
Assessing the contribution of dilution of the donor emission intensity (left) and the contribution 
of acceptor direct excitation on acceptor emission intensity (right) due to increasing calpastatin 
domain I. The area of the donor and acceptor peaks is calculated as the sum of intensity. A) 
CIOSA-FIASH (2 uM) (510-545 nm) serves as donor to calpastatin domain I C151S241-TMR (n=2) 
(circles) or calpastatin domain I S24i (squares) (560-620 nm). B) Ci05A-eGFP (1 uM) (480-540 
nm) serves as donor to calpastatin domain I C142S241-AF546 (circles) or calpastatin domain I S241 
(squares) (n=2, donor emission control) (550-620 nm). Based on a single assay unless otherwise 
noted. % indicates individual control measurements that have been duplicated. 
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not to the extent as for acceptor-calpastatin. This suggests that FRET is the major factor of the 
observed donor quenching. 
Direct excitation of the acceptor fluorophore likely contributed to the increasing acceptor 
emission peak due to the fact that the ratio does not reach saturation despite the fixed amount of 
donor-calpain. As the donor emission reaches maximal quenching, a continual increase in 
acceptor emission due to direct excitation would increase the ratio. To assess the contribution of 
direct excitation to the signal, the acceptor-calpastatin emission response to the donor excitation 
wavelength was measured in the absence of donor-calpain. The area of the acceptor emission 
peak increases as the acceptor-calpastatin concentration increases indicating direct excitation of 
the acceptor fluorophore in the absence of the donor fluorophore. The calpastatin domain I 
C151S241-TMR emission peak area increased 2.57±0.38 (n=2) in the presence of CiosA-FlAsH but 
also increased 2.23 (n=l) in the absence of donor calpain (0-10 uM) (figure 3.6 A). The 
calpastatin domain I Ci42S24i-AF546 emission peak area increased 4.19 (n=l) in the presence of 
CiosA-eGFP but also increased 4.28 (n=l) in the absence of donor calpain (0-10 uM) (figure 3.6 
B). The direct excitation acceptor emission peak is lower in the absence of donor calpain. This 
difference identifies some energy transfer taking place between the donor and acceptor 
fluorophores. However the continual increase in the acceptor emission due to acceptor direct 
excitation does not allow saturation of the ratio. 
Calcium Dependence of the Two Component Strategy A second approach to test for FRET 
between donor-calpain and acceptor-calpastatin was to add increasing amounts of calcium to 
fixed concentrations of calpastatin and calpain. As shown in figure 3.4, there was a calcium 
dependent increase in the emission ratio at the lowest acceptor-calpastatin concentration (1 uM). 
Based on these findings, calpastatin and calpain were used for subsequent assays at a 2:1 molar 
ratio to allow direct measurement of binding between the fluorogenic pair of proteins in response 
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to calcium. Using an excitation wavelength specific to the donor fluorophore (460 nm), emission 
spectra (480/495 to 650 nm) were collected to monitor the changes in the donor and acceptor 
peaks in response to the increasing calcium concentration. These spectra demonstrated a dose 
responsive quenching of the donor emission (figure 3.7). Expressing the donor emission 
quenching and slight acceptor emission increase as a ratio of EmA/EmD revealed a cooperative 
increase. Furthermore, the ratio leveled off as expected demonstrating saturation of ligand 
binding in this assay format. This calcium dependent increase in the FRET ratio observed from 
zero free calcium to saturation (0.8-2 mM) was expressed as a percent increase of the ratio. 
Pooling data and averaging the percent increase for the six different acceptor-calpastatin domain I 
peptides, there was a 332.56%±48.64 (n=6) increase for Ci05A-FlAsH and 95.87%±10.02 (n=6) 
increase for CiosA-eGFP as donors. However similar data analysis using the two acceptor-
calpastatin control peptides as acceptors only demonstrated a 18.18% (n=l) increase for C105A-
FlAsH and 15.09%±1.24 (n=2) increase for C105A-eGFP (figure 3.8). Thus specific placement of 
the acceptor fluorophores near the amino-terminus of the calpastatin domain I peptides resulted in 
approximately a 6 fold (CiosA-eGFP) or 18 fold (CiosA-FlAsH) increase in signal. The ratio 
increase in response to calcium and decrease in response to EGTA demonstrate the calcium 
dependence of the FRET signal. These observations validate the signal is a detection of the 
binding of acceptor-calpastatin to the active conformation of donor-calpain in response to 
calcium. 
A Strategy for Detecting Active Endogenous Calpain The two component FRET binding pair 
requires calpain with a donor fluorophore at the carboxy-terminus of the catalytic subunit. 
Utilizing this design in situ would require over-expression of QosA-eGFP or Q05A-4C followed 
by in situ labeling using FlAsH. A method for detecting activation of endogenous calpain would 
detect physiologically relevant calpain in situ. A three component binding system exploiting 
calpastatin's calcium dependent interaction with the conventional calpains was designed. This 
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Figure 3.7 Emission Scan Response to Calcium Concentration 
To assess the changes in donor and acceptor emission in response to the calcium concentration, 
binding assays were performed using A) CiosA-FlAsH (2 uM) or B) CiosA-eGFP (1 uM) and 
calpastatin domain I C148S241-TMR (2 uM) with increasing calcium followed by EGTA addition 
to reverse binding. Left panels show emission scans (5.0 nm slits) at the free calcium 
concentrations indicated by the inset. The right panels show the EmA/EmD ratio plotted relative 
to increasing calcium concentration (circles) and after EGTA addition (squares). Assays shown 
are representative for the six acceptor-calpastatin peptides studied. 
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Figure 3.8 Comparison of Binding Assays with Various Donor-Calpain and Acceptor-
Calpastatin Pairs 
The ratio of acceptor emission over donor emission was used to assess FRET relative to calcium 
concentration for a series of binding assays. Using data from assays similar to those in figure 3.7, 
the percent change in ratio was determined from the basal ratio at 0 uM free calcium to the 
average ratio at saturation (0.8-2 mM). C^A-FlAsH (A) or CiosA-eGFP (B) served as donor to 
each of the acceptor-calpastatin domain I peptides: S24i (light blue), Ci42S24i (blue), Ci48S24i 
(coral), and Ci5iS24i (yellow). Results shown are representative of two assays unless otherwise 
indicated (+=1). 
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design utilizes fluorogenically modified calpastatin domain I subdomain A and subdomain C 
peptides to bind unmodified calpain 2 C105A. In the presence of calcium AF647-calpastatin 
subdomain A (acceptor) and AF568-calpastatin subdomain C (donor) are predicted to bind 
calpain bringing the fluorophore pair within approximately a 51 A distance. This distance, 
although greater than the distance between the bound catalytic subunit carboxy-terminus and 
calpastatin domain I amino-terminus, is within the manufacturer determined 82 A Ro for AF568 
as donor to AF647 (Invitrogen-Molecular Probes). To screen for a combination of fluorogenic 
calpastatin domain I subdomain A and subdomain C peptides that generate FRET, twelve 
different pairs of donor-calpastatin subdomain C and acceptor-calpastatin subdomain A peptides 
were tested in binding assays. Emission spectra (570 to 720 nm) in response to excitation of the 
donor AF568 fluorophore (515 nm) did not indicate a calcium dependent quenching of the donor 
AF568 peak or an increase in the acceptor AF647 peak (figure 3.9 A). Thus there was not a 
detectable transfer of energy between the bound, fluorophore modified subdomains. 
The two component strategy utilizing a donor-calpain and acceptor-calpastatin was 
employed in order to verify that each different subdomain peptide is binding calpain. In a series 
of assays CiosA-eGFP served as donor to all eight AF546 modified calpastatin subdomain A and 
C peptides. The subdomain A peptides with an amino-terminal AF546 produced an average 
calcium dependent increase in FRET signal of 41.97%±6.57 (n=3) while the control peptide 
(subdomain A-AF456) only produced a FRET signal increase of 3.58% (n=l) (figure 3.9 B). 
This trend was similar to that observed for whole domain I and confirmed the ability of 
fluorophore modified calpastatin subdomain A peptides to bind calpain. The AF546-subdomain 
C peptides however showed only a 5.66%±6.31 (n=4) calcium dependent increase in FRET ratio. 
Thus there was minimal detection of energy transfer between the bound CiosA-eGFP and 
calpastatin domain I subdomain C-AF546 peptides. 
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Figure 3.9 Preliminary Tests Using Fluorogenic Calpastatin Subdomain Peptides 
A) Initial donor emission of calpastatin domain I subdomain C S24iC246-AF568 ( ) was 
established in the absence of acceptor by exciting at 515 nm while scanning for emission between 
570-720 nm using 2.5 nm excitation slits and 5.0 nm emission slits. Emission scans were 
performed following addition of 1) calpastatin domain I subdomain A Ci48-AF647 (2 uM) 
( ), 2) calcium (11 mM) (—), and 3) EGTA (22 mM) ( ) to show reversal of binding. 
Assay shown is representative for the twelve subdomain C-AF568, subdomain A-AF647 peptide 
combinations studied. B) To assess binding of acceptor-calpastatin subdomain peptides, changes 
in the FRET ratio were calculated for a series of binding assays using calpastatin subdomain A-
AF546 or subdomain C-AF546 peptides to bind CiosA-eGFP (1 uM). The percent increase in 
ratio (EmA/EmD) was determined in response to calcium (11 mM) for the eight acceptor-
calpastatin domain I subdomain peptides (2 uM). Inset designates the different AF546-
calpastatin domain I subdomain peptides, subdomain A (SdA) or subdomain C (SdC). Results 
shown are from single assays. 
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In Vitro Applications for a Calpastatin Based FRET Biosensor to Detect Active 
Calpain 
The studies using purified components established the ability to detect the energy transfer 
upon binding of acceptor-calpastatin to donor-calpain in response to calcium. To begin assessing 
if this design has the potential to work in the complex cellular environment, a crude BL21(DE3) 
cell lysate containing CiosA-eGFP was used in place of the partially purified CiosA-eGFP. 
Addition of one of the eight different acceptor modified calpastatin domain I peptides in a series 
of assays using E. coli cell lysate containing CiosA-eGFP (0.5 uM) followed by addition of 
calcium resulted in quenching of the donor peak and an increase in the acceptor peak during 
emission scans (figure 3.10 A). The percent increase in the EmA/EmD ratio upon calcium addition 
was calculated for all eight pairs (figure 3.10 B). An average increase in EmA/EmD of 
41.24%±5.88 (n=6) was observed for the amino-terminal acceptor-calpastatin domain I peptides 
relative to a -0.46%±4.54 (n=2) change observed in the presence of nonspecifically modified 
AF546-calpastatin domain I peptides. These results demonstrated energy transfer can be detected 
for the binding of acceptor-calpastatin domain I to CiosA-eGFP in a crude cell lysate. 
In eukaryotic cells, endogenous calpastatin and calpain will both be present and expected 
to bind the CiosA-eGFP or acceptor-calpastatin domain I. In order to gain insight into the impact 
these proteins may pose to the FRET signal when applied in cells, the ability of calpastatin, 
calpain 1, or calpain 2 to compete for the binding of calpastatin domain I Ci48S24i-AF546 to 
CiosA-eGFP was determined. The calcium dependent increase in EmA/EmD due to the binding of 
calpastatin domain I Ci48S24i-AF546 to CiosA-eGFP was determined in the presence of unlabeled 
calpastatin domain I S241, WT calpain 1 or calpain 2 C105A. As expected calpastatin and calpain 
2 demonstrated a calcium dependent, dose responsive reduction in the FRET ratio (figure 3.11 
A). Importantly though, calpain 1 also displayed a dose dependent reduction in the ratio in 
43 
1000 B 
480 500 520 540 560 5S0 
Wavelength (nm) 
BOO 620 
I 
60 
50 
40 
*> 30 
20 
? 10 
-10 TMR 
•IJjl 
% 
u 
'if1 
1 W 
Alexa 546 
Figure 3.10 Detecting Calpain-eGFP in a Crude Cell Lysate 
A) Initial donor emission of a crude lysate from E. coli expressing CiosA-eGFP (0.5 uM eGFP) 
was established in the absence of acceptor-calpastatin by exciting at 460 nm while scanning for 
emission between 480-650 nm ( ) (5.0 nm slits). Emission scans were performed following 
addition of 1) calpastatin domain I C151S241-TMR (2 uM) ( ), 2) calcium (14 mM) ( ), and 
3) EGTA (24 mM) (—) to show reversal of binding. Assay shown is representative for the six 
acceptor-calpastatin peptides studied. B) Changes in the FRET ratio were calculated for a series 
of binding assays using crude lysate from E. coli expressing CiosA-eGFP (0.5 uM eGFP) as 
donor to each acceptor-calpastatin domain I peptide (2 uM): S241 (light blue), C142S241 (blue), 
C148S241 (coral), or C151S241 (yellow). The percent increase in ratio (EmA/EmD) was determined in 
response to calcium (14 mM). Results shown are representative of single assays for each pair 
studied. 
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Figure 3.11 Unmodified Calpastatin or Calpain Competes with Calpastatin Domain 1 
C148S24i-AF546 Binding to C105A-eGFP 
To assess the ability of endogenous calpastatin or calpain to compete for the binding of Q05A-
eGFP to calpastatin domain I Ci48S24i-AF546, unlabeled calpastatin, calpain 1, or calpain 2 were 
used as competitors. A) The change in EmA/EmD ratio upon addition of calcium (10 mM) was 
determined for a series of binding assays containing unlabeled calpastatin domain I S24i (0-2 uM), 
porcine calpain 1 (0-1 uM), or rat calpain 2 Q05A (0-luM) with CiosA-eGFP (1 uM or 0.5 uM 
with calpain 1) and calpastatin domain I Ci48S24rAF546 (1 uM or 0.5 uM with calpain 1). 
Results are each from a single experiment. B) In a binding assay with calpastatin domain I 
Ci48S24i-AF546 (1 uM) bound to CiosA-eGFP (1 uM) in the presence of calcium (10 mM), 
unlabeled calpastatin domain I S24i was then added up to 13 uM to compete for binding of the 
calpastatin domain I Ci48S24i-AF546. The ratio of acceptor emission over donor emission was 
determined at 0 uM (light blue) and 13 uM (blue) unlabeled calpastatin (n=l). 
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response to calcium. These results confirm calpastatin domain I and both calpains 1 and 2 do 
compete for binding and indicate their presence in situ could decrease the FRET signal. In a 
similar assay unlabeled calpastatin domain I S241 was added to prebound calpastatin domain I 
Ci4gS24i-AF546 and CiosA-eGFP (figure 3.11 B). Up to 13 uM unlabeled calpastatin domain I 
was unable to displace the bound calpastatin domain 1 Ci4gS24i-AF546 from CiosA-eGFP. This 
argues that calpastatin may have a slow off rate of binding to calpain 2. 
Endogenous calpain substrates will also be present in cells. Binding of these substrates in 
situ may also compete for acceptor-calpastatin binding to CiosA-eGFP and potentially decrease 
the FRET signal. In order to investigate the potential for competitive binding, one of calpain's 
endogenous substrates the cytoplasmic tail (CT) of Pi integrin and an in vitro substrate, a-casein, 
were used as competitors for the binding of calpastatin domain I Ci4gS24i-AF546 to CiosA-eGFP. 
The calcium dependent increase in EmA/EmD due to the binding of calpastatin domain I Ci48S24i-
AF546 to CiosA-eGFP was determined in the presence of partially purified Pi integrin-CT or a-
casein. Up to 20 uM partially purified pi integrin-CT or 20 uM a-casein did not affect the 
increase in FRET ratio upon calcium addition (figure 3.12 A). In similar assays pi integrin or a-
casein were preincubated with CiosA-eGFP in the presence of calcium to favor binding of the 
substrates. Addition of calpastatin domain I Ci4gS24i-AF546 revealed no measurable change in 
the ratio (data not shown) in contrast to the effect observed with unlabeled calpastatin. Thus 
neither substrate tested competed for the FRET signal. To verify that calpain is actually binding 
the Pi integrin-CT, WT calpain 2 was allowed to proteolyze the partially purified Pi integrin-CT. 
As early as 10 minutes calpain cleaved the pi integrin demonstrating that calpain must be binding 
the substrate (figure 3.12 B). Although casein is not an endogenous substrate it is a very good in 
vitro substrate for calpain 2. The inability of even a-casein to compete for acceptor-calpastatin 
binding indicates many substrates may not pose a problem as competitors in situ. 
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Figure 3.12 Calpain Substrates do not Compete with Calpastatin Domain 1 Ci4sS24i-AF546 
Binding to CjosA-eGFP 
To assess the ability of endogenous substrates to compete for the binding of CiosA-eGFP to 
calpastatin domain I Ci48S24i-AF546, partially purified Pi integrin cytoplasmic tail or a-casein 
were used as competitors. A) The change in ratio upon addition of calcium (10 mM) was 
determined for a series of binding assays containing partially purified Pi integrin cytoplasmic tail 
or ct-casein (0-20 uM) with CiosA-eGFP (1 uM) and calpastatin domain I Ci4gS24i- AF546 (1 uM). 
Competitor concentrations are 0 uM (cyan), 1 uM (blue), 10 uM (red), and 20 uM (yellow). 
Results are each from a single assay. B) To verify calpain's ability to bind the substrate the pi 
integrin cytoplasmic tail was proteolyzed by WT calpain 2. Recombinant rat calpain 2 (50 
ng/uL) was incubated with the partially purified Pi integrin cytoplasmic tail (0.5 ng/uL) in the 
presence of calcium (10 mM) at 22°C. Aliquots were treated with SDS sample buffer after 0, 10, 
and 60 minutes and analyzed by electrophoresis. Migration of molecular weight markers (USB) 
is indicated in kDa. Band corresponding to Pi integrin is indicated by an arrow. Gel pictured is 
10% acrylamide and stained with Coomassie blue-amido black. 
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Chapter 4 DISCUSSION 
Two strategies were tested to develop a sensor for detecting active calpain. The strategy 
utilizing calpain 2 modified with a donor fluorophore at the carboxy-terminus of domain IV to 
donate energy to calpastatin domain I modified with an amino-terminal acceptor fluorophore did 
generate FRET. Two different donor fluorophores were utilized, FlAsH and eGFP. The 
biarsenic dye FlAsH is a derivative of fluorescein where as eGFP is an expressible fluorogenic 
protein derived from jelly fish. FlAsH is a small dye where as eGFP consists of a chromophore 
protected by a bulky (3-barrel. The location of the chromophore in the barrel of eGFP adds -30 A 
to the distance between the fluorophores (53). The actual distance between eGFP and the 
acceptor fluorophore would shift from ~31 A to ~61 A. This increase in fluorophore distance is 
closer to the maximum R<, for many fluorophore pairs (60 A). Thus the smaller size of FlAsH is 
predicted to allow it to maintain a closer distance to the bound acceptor fluorophores increasing 
the efficiency in energy transfer. 
There is also a difference in the emission spectra of the two donor fluorophores. FlAsH's 
emission peak is shifted approximately 20 nm longer than that of eGFP, 528 nm vs. 508 nm. The 
shifted donor emission would allow greater overlap of the donor emission and acceptor 
absorbance peaks generating more efficient transfer of energy from FlAsH than eGFP. In fact, 
there was a greater calcium dependent increase in ratio for FlAsH as donor vs. eGFP (figure 3.8). 
Also, the acceptor direct excitation seemed closer to the FRET acceptor emission for eGFP as 
donor vs. FlAsH (figure 3.6). These results support the speculation that FlAsH may transfer 
energy more efficiently to TMR and AF546 than eGFP. 
Orientation and distance of the fluorophore pair relative to each other are important 
factors for the efficiency of energy transfer. Preferentially positioning the acceptor fluorophore at 
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three different locations near the amino-terminus of calpastatin domain I (Ci42, CMS, or Cm) 
slightly altered the distance (2-10 A) and potentially the orientation between the fluorophore 
pairs. There was not a superior acceptor fluorophore position out of the three tested (figure 3.8). 
Both TMR and AF546 have very similar excitation and emission spectra however Alexa Fluor 
dyes are among the brightest and most photostable fluorescent dyes (Alexa Fluor Dyes 
Invitrogen). Despite the advantages of the AF546 neither acceptor fluorophore proved superior 
compared to the other in these studies. 
The fluorogenically modified calpastatin peptides, despite containing a single cysteine 
residue, were modified with 2 or more fluorophores per peptide based on the determined 
stoichiometry of peptide labeling. Although more selective for thiols, maleimides have the 
capacity to interact with the e amino group of lysines at neutral pH and/or at high fluorophore-
maleimide concentrations (4). The fluorogenic peptide conjugation assays were performed at pH 
7.0 with a 13 fold molar excess of fluorophore-maleimide to peptide (40-80 uM). Calpastatin 
domain I contains 19 lysine residues with 11 in subdomain A and 8 in subdomain C that may 
have been nonspecifically conjugated under the assay conditions. Modification of calpastatin 
domain I S24i, a peptide containing no cysteine residue, established that approximately half of 
these peptides were nonspecifically coupled with TMR. In order to bias selectivity of 
modification towards cysteine residues the pH of the reaction was lowered to 6.0 and the 
incubation time for modification was decreased to thirty minutes. Neither of these changes 
decreased the estimated stoichiometry of TMR labeling of calpastatin domain I S24i (data not 
shown). 
When the AF546/TMR modified calpastatin domain I S24i peptides served as acceptor to 
CiosA-eGFP in binding assays the increase in the EmA/EmD ratio was approximately four fold 
lower than that of the peptides modified at an amino-terminal cysteine (figure 3.8 B). There are 
two possible contributing factors for the lack of detectable energy transfer from eGFP. First, 
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approximately half the bound calpastatin domain I S24i possess a TMR to accept energy transfer 
from the eGFP lowering the detectable signal. Also, the position of acceptor fluorophore on the 
calpastatin peptide is important to the efficiency of energy transfer. The calpastatin domain I 
peptides encoding a cysteine are all preferentially labeled near the amino-terminus with an 
acceptor fluorophore. The position of modification of the nonspecifically labeled domain I S24] is 
undetermined and likely sporadic. The nonspecifically modified peptides are likely a population 
with mixed acceptor fluorophore localized along the length of the peptide. It is predicted that the 
positioning of the acceptor fluorophore at the amino-terminus of bound calpastatin domain I 
allowed for more efficient transfer from eGFP than distal locations. A construct expressing 
calpastatin domain I C24i was created during the subcloning process but was not expressed or 
purified. Modification of this peptide would specifically direct acceptor fluorophore labeling to 
the carboxy-terminus of calpastatin domain I. Calpastatin domain IC241-TMR and domain I C241-
AF546 could serve as acceptors to CiosA-eGFP in binding assays to demonstrate if the amino-
terminal localization of acceptor fluorophore is essential for efficient energy transfer. A 
detectable signal would reveal that an acceptor fluorophore preferentially placed towards the 
carboxy-terminus of calpastatin domain I can also accept energy transfer from eGFP at the 
carboxy-terminus of calpain domain IV. 
Two different approaches were utilized to assess energy transfer from the donor on the 
carboxy-terminus of calpain 2 domain IV to the acceptor on the amino-terminus of bound 
calpastatin domain I. The two assay strategies utilized either increasing acceptor-calpastatin 
concentration or increasing calcium concentration. The assays employing increasing acceptor-
calpastatin displayed high direct excitation of the acceptor. The contribution of direct excitation 
of the acceptor fluorophore to the acceptor emission prevented the EmA/EmD ratio from 
demonstrating saturation of binding of the QosA-eGFP and CiosA-FlAsH. In addition, the 
acceptor emission spectra shifted as the acceptor-calpastatin concentration increased. This shift 
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affected the EmA/EmD ratio calculated from the relative fluorescent units at the peak of the 
acceptor emission spectra at the low acceptor-calpastatin concentrations (1-4 uM). For this 
reason the area under the donor and acceptor emission peaks was used to calculate ratios for these 
assays. The shift in acceptor emission peak was not a problem however when donor-CiosA and 
acceptor-calpastatin concentrations were used at a fixed concentration. Thus the assays utilizing 
1 uM CiojA-eGFP, 2 uM acceptor-calpastatin and increasing calcium concentration circumvented 
the effects of high acceptor-calpastatin concentration. 
Ultimately, this tool will be of the most use in cells to demonstrate spatial and temporal 
activation of calpain. As expected the binding of acceptor-calpastatin to CiosA-eGFP was 
specific enough to work in the crude environment of an E. coli cell lysate. The assays using 
calpain 1 as a competitor indicate calpastatin domain I Ci4gS24i-AF546 also binds calpain 1. 
Utilizing a crude cell lysate containing calpain 1-eGFP fusion protein could prove the ability of 
calpain 1 to bind calpastatin domain I Ci48S24rAF546 during in vitro binding assays. Employing 
cells expressing either calpain 2-eGFP or calpain 1-eGFP, a comparison could be made of the 
potential differential spatial and temporal subcellular localization of the two classical calpain 
isoforms. The assays using calpastatin domain I S24i, calpain 1, or calpain 2 C105A as competitors 
also demonstrated there would be some signal interference due to endogenous calpastatin and 
calpain. The levels of endogenous calpain and calpastatin expression are different between cell 
types. Human platelet cells display calpain 1 and calpastatin but little to no calpain 2. Bovine 
cardiac muscle cells contain more calpain 2 than calpain 1 and calpastatin in excess of both 
proteases (18, 57). Also, full length calpastatin contains four inhibitory domains to bind up to 
four calpain molecules. Therefore the potential level of signal interference due to these three 
endogenous proteins will depend on the type of cells employed in the study. For example, the 
Capn4-/- murine fibroblasts deficient in the calpain small subunit demonstrate a lack of calpain 
activity by casein zymography (13). Alternatively, siRNA have been used to knock down calpain 
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1 in human breast cancer cells (MCF-7) which lack expression of calpain 2 (62). Thus 
interference could be reduced by selecting a cell type low or deficient in endogenous classical 
calpains and/or calpastatin. 
Of further interest was the potential for endogenous calpain substrates to compete for the 
binding of acceptor-calpastatin to CiosA-eGFP. As demonstrated by competition using the 
endogenous substrate Pi integrin-CT and the in vitro substrate a-casein, it appears that most 
substrates should not inflict this complication. This is likely due to calpastatin's high affinity for 
calpain (k,=3 nM) (42). Calpastatin's ability to displace bound substrate could prevent calpain 
from cleaving substrate in the event of unwanted activation. This may be an important protective 
role for calpastatin in vivo. 
In situ overexpression of calpain 2-eGFP and microinjection of calpastatin domain I-
acceptor will be necessary to utilize this strategy in cells. Increased calpain activity is associated 
with photoreceptor degeneration, failure of cell-cycle arrest in mammary and lung carcinoma 
cells, amyloid plaque and neurofibrillary tangle formation in Alzheimer's disease, and apoptosis 
(26, 27, 45, 46). Alternatively, increased calpastatin expression is associated with reduced 
formation of lamella and altered gene expression (7). Depending on the cell type being used 
overexpressing calpain and injection of calpastatin domain I in cells could have adverse effects 
upon calpain activation. To avoid such issues the CI05A calpain 2 inactive mutant could be used 
in place of WT calpain 2. If observing calpain dependent focal adhesion turnover in fibroblasts, 
added calpastatin domain I-acceptor may inhibit endogenous calpain and prevent the expected 
adhesion turnover (16). Acceptor-calpastatin domain I could be injected at different 
concentrations to find one that does not inhibit adhesion turnover but still allows signal detection. 
A similar probe using fluorogenic calpastatin subdomain A and C peptides to bind calpain would 
be capable of detecting endogenous calpain without inhibition. Neither of the calpastatin 
subdomain peptides contain a intact subdomain B region. Disrupting the subdomain B region 
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diminishes its inhibition (1). Thus injection of the subdomain A and C peptides would not inhibit 
endogenous calpains allowing for detection of subcellular activation during cellular processes 
such as focal adhesion turnover. 
The binding of calpastatin to calpain has been reported to occur in the absence of calcium 
based on data obtained by co-immunoprecipitation (38). This result contradicts the long 
established calcium dependent binding interaction of calpastatin to calpain that was demonstrated 
by several methods (8, 63). The cooperative increase in the EmA/EmD ratio directly demonstrates 
binding between calpain and calpastatin in response to calcium and a reversal of binding in 
response to the calcium chelator EGTA (figure 3.7). Immunoprecipitate of CiosA-eGFP utilizing 
an antibody for eGFP co-precipitates calpastatin domain I only in the presence of calcium (Croall 
unpublished data). These data do not support a calcium independent association between 
calpastatin and calpain. 
Unfortunately, subdomain C-AF568 did not demonstrate energy transfer to subdomain A-
AF647 in vitro. Similarly, CiosA-eGFP did not demonstrate energy transfer to subdomain C-
AF546 despite an approximately 31 A distance between the fluorophores when bound. The lack 
of signal observed with the fluorogenic subdomain C peptides may be due to multiple problems 
including fiuorophore distance, unfavorable fluorophore orientation and/or lack of binding. The 
distance from the carboxy-terminus of domain IV of calpain to the carboxy-terminus of bound 
calpastatin domain I subdomain C is the same distance estimated to the amino-terminus of bound 
subdomain A. Thus fluorophore distance is unlikely to explain the inability to detect energy 
transfer from CiosA-eGFP to subdomain C-AF546 peptides. The amino-terminus of calpain 
bound calpastatin domain I subdomain A is estimated to be 50 A from the carboxy-terminus of 
calpain bound calpastatin domain I subdomain C. This distance is close to the maximum Ro for 
many fluorophore pairs (60 A). A perpendicular fluorophore orientation results in a zero net rate 
of energy transfer. If bound subdomain C-AF546 is not in the proper orientation energy will not 
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be transferred from eGFP at the carboxy-terminus of calpain domain IV despite the distance. 
Potentially adding to the problem the acceptor fluorophore AF647 demonstrated decreased 
intensity compared to TMR, AF546, and AF568. This decreases the overlap of the AF568 
emission spectra with the AF647 excitation spectra decreasing the potential for energy transfer. 
Thus there could be a combined problem of fluorophore distance, orientation and acceptor 
fluorophore intensity for detecting the binding of subdomain C-AF568 and subdomain A-AF647 
to calpain. 
There is concern whether the acceptor modified calpastatin domain I subdomain C 
peptides are binding calpain. Calpastatin domain I subdomain C L235 and F239 are the main 
residues binding the two hydrophobic pockets of calpain domain VI. Positions 237 and 241 of 
calpastatin subdomain C are very close to these important residues. Fluorogenic modification of 
subdomain C at positions C237 and C24i may sterically hinder binding of subdomain C to calpain 
domain VI. Calpastatin subdomain C S241C246 and S241C256 however direct modification to 
locations distal to the identified subdomain C calpain domain VI interaction sites. Thus 
calpastatin subdomain C labeled at position 246 or 256 should not affect subdomain C's ability to 
bind calpain. There is evidence however that the calpain heterodimer in the presence of calcium 
and in the absence of substrate or calpastatin is unstable and dissociates. The small subunit may 
precipitate under such conditions, thus calpain would no longer be a heterodimer containing 
domain VI for calpastatin subdomain C to bind. The subdomain A and C peptides do not 
constitute a whole domain and binding may not be sufficient to maintain calpain stability. This 
could also explain the inability to detect energy transfer from the eGFP on the carboxy-terminus 
of calpain domain IV to subdomain C-AF546. 
A series of future experiments are proposed to investigate whether the problem is due to 
acceptor fluorophore position on calpastatin or subunit dissociation. First, a construct expressing 
calpastatin domain I S241C246 could be engineered by mutating T246 to encode a cysteine in the 
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construct containing the calpastatin domain I S24i sequence. Purified calpastatin domain I 
S241C246 modified with AF546 could serve as acceptor to Ci05A-eGFP to provide information 
about subdomain C binding. Calpastatin domain I S241C246-AF546 contains the subdomain A and 
B binding sites. If small subunit dissociation is the issue the presence of the subdomain A and B 
binding sites should increase heterodimer stability. Thus there should be a FRET signal with the 
acceptor fluorophore at position 246. Second, it has been shown that a-casein does not compete 
for binding of calpastatin domain I Ci4gS24i-AF546 to QosA-eGFP. Similar to the effect of 
calpastatin, calpain substrates are expected to stabilize the heterodimer in the presence of calcium 
(44). Calpastatin subdomain C C246S24i-AF546 could serve as acceptor to CiosA-eGFP in the 
presence of a-casein to prevent small subunit dissociation. The detection of energy transfer upon 
calcium addition in these assays would support the occurrence of subunit dissociation in the 
absence of a-casein. If this proves to be true, the assays utilizing calpastatin subdomain C-AF568 
as donor to subdomain A-AF647 should be repeated with the inclusion of a-casein. 
Last, the binding of a calpastatin domain to calpain orients the amino-terminus of 
subdomain A inverted to that of subdomain C (figure 1.3). The orientation of the amino-terminal 
fluorophore/cysteine positions of domain I (subdomain A) to calpain domain IV carboxy-
terminus may be more comparable to amino-terminal positions of subdomain C. Residues 237, 
241, 246, and 256 used to date as fluorophore modifying locations on calpastatin subdomain C 
peptides are at the carboxy-terminus. Specifically placing a fluorophore at the amino-terminus of 
subdomain C may put the fluorophore in a more favorable orientation for energy transfer. The 
amino-terminus of calpastatin subdomain C is estimated to be -37 A from the carboxy-terminus 
of calpain domain IV and ~51 A from the amino-terminus of calpastatin domain I (subdomain A). 
Calpastatin residue S223 is at the amino-terminus of subdomain C but not too close to the key 
residues responsible for binding calpain domain VI. Constructs encoding calpastatin domain I 
S24i and/or subdomain C S241 could be mutated to encode a cysteine at position 223. Calpastatin 
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domain I C223S241 and subdomain C C223S241 could be modified with AF546 to serve as acceptors 
to CI05A-eGFP in binding assays. In the absence of positive results from the experiments above, 
the detection of energy transfer in these assays would support acceptor fluorophore orientation at 
the carboxy-terminus of subdomain C as unfavorable. If these assays demonstrate a FRET signal, 
calpastatin subdomain C C233S241 could then be modified with AF568 to serve as donor to the 
calpastatin subdomain A-AF647 peptides to detect binding to unlabeled calpain. An inability to 
detect energy transfer even in the presence of a-casein would suggest there is insufficient spectral 
overlap between the AF568 and AF647 fluorophore pair to allow energy transfer possibly due to 
the weak AF647 signal as mentioned above. A fluorophore pair with greater spectral overlap 
may remedy this problem such as AF546 as donor to Alexa Fluor 594. 
A novel method to detect endogenous calpastatin by FRET was recently described (19). 
The purpose of the study was to detect endogenous calpastatin in a heated meat extract using 
AF546 modified mouse anti-calpastatin IgG as donor to AF594 modified calpain 1 that could be 
brought together when bound to calpastatin. However, the antibody and calpain 1 were randomly 
modified with fluorophores and the distance between the antibody and calpain binding site on 
calpastatin was not defined. Thus the distance between the fluorophores of the bound fluorogenic 
proteins of the sensor was unknown. Despite the flaws in this design, the ability of the FRET 
sensor to detect calpastatin in the meat extract was demonstrated by a reduction in the EmD/EmA 
ratio in response to calpastatin addition (120-180 ng/mL). Binding of the sensor to calpastatin 
was implied by these competition studies. To verify the sensor is binding calpastatin in a calcium 
dependent manner, the change in the EmD/EmA ratio in response to increasing calcium 
concentration could be monitored in the presence of several concentrations of purified calpastatin. 
To ensure the signal is a detection of sensor binding to calpastatin, this experiment could be 
performed in the absence of calpastatin. These results could validate the ability of this strategy to 
generate a FRET signal in the presence of calpastatin despite the undefined binding interaction 
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and unknown fluorophore separation. In contrast, the strategy detecting the binding of donor-
calpain and acceptor-calpastatin, as developed in this thesis, has the advantage of a well 
characterized binding interaction and the ability to estimate the distance between the fluorophore 
pair of the bound fluorogenic calpain and calpastatin. However, it may be possible to detect 
endogenous calpain using an AF546 modified anti-calpain antibody (AF546-Ab) to serve as 
donor to AF594 modified calpastatin domain I. Depending on the specificity of the antibody it 
may also be possible to visualize activation of the different classical calpain isoforms. Success of 
this sensor would depend on the anti-calpain antibody binding to a region that does not sterically 
hinder binding of calpastatin domain I to calpain and to bind a region that is within 60 A distance 
from the AF594 on the calpastatin domain I. In the absence of a pair of fluorogenic calpastatin 
subdomain peptides that bind calpain to generate FRET, application of an AF546-Ab/AF594-
calpastatin could be an alternative strategy to detect endogenous calpain. 
Future studies may also be aimed at developing new designs of a FRET probe to detect 
active endogenous calpain. One design would be to develop a probe that will detect a loss of 
FRET due to cleavage specifically by calpain. This has been previously attempted by expressing 
the a-spectrin calpain cleavage site between eCFP and eYFP with and without an amino terminal 
PDZ-binding site (52, 59). The PDZ-binding site directed localization of the fusion protein to 
areas of synaptic calpain activation in hippocampal neurons. This generated positive results 
biased to demonstrate calpain activation specifically at these locations in cells. This sensor was 
also expressed in mouse tibialis anterior muscles without the PDZ-binding site to demonstrate 
calpain activation due to calcium injection. As previously mentioned, a-spectrin can also be 
cleaved by caspase-3 indicating the loss of FRET signal for the eCFP/a-spectrin/eYFP sensor is 
not exclusively diagnostic for calpain activation. To overcome this limitation the Pi integrin-CT 
calpain cleavage site could be tethered to calpastatin subdomain A and expressed between CFP 
and YFP. The unstructured nature of pi integrin-CT and subdomain A would allow FRET 
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between CFP and YFP in the absence of cleavage (43). Upon binding calpain, cleavage of the pi 
integrin-CT would release a fluorophore allowing detection of a loss of FRET signal. The ability 
of a calpain molecule to cleave multiple probes increases the sensitivity of the signal for the 
cleavage probe compared to the binding probe. Importantly, the fusion of a calpastatin binding 
region and calpain cleavage site could improve the specificity of the loss of FRET sensor. 
Application of the calpain-eGFP and calpastatin domain I-AF546 to in situ studies may 
provide a useful tool for detecting where and when calpain is active during both pathological and 
physiological cellular processes. To accomplish this, an optimum concentration of acceptor-
calpastatin for injection into a cell line expressing calpain-eGFP will need to be established. 
Unfortunately competition due to both endogenous calpains and calpastatin will be concern for 
this strategy in cells. The strategy to detect active calpain using the binding of fluorophore 
modified calpastatin subdomain A and C peptides would have the advantage of detecting 
endogenous calpain without inhibition. Upcoming studies are therefore aimed to continue the 
development of probes that will detect activation of endogenous calpain in situ by exploiting the 
calpain-calpastatin binding interaction. 
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